Changing the way
we see the gut

UK hospitals to harness the power of AI gut-imaging to aid treatment of Crohn’s Disease  £1.2M National Institute for Health and Care Research (NIHR) funding will see more than 10 UK NHS hospitals (3400 patients) utilising GIQuant  to improve analysis and management of Crohn’s Disease Inflammatory Bowel Disease (IBD) costs the NHS £720 million a […]

When COVID-19 appeared on the scene a lot of strange, interesting, and terrible things happened in the world. Of particular interest to me was how many companies in the MedTech space pivoted their technology to meet some aspect of the pandemic. As one of the most niche companies out there, we at Motilent kept our […]

Nothing makes more sense than the ‘treat to target concept’ in IBD. Every patient is different, IBD is complex, keeping a close eye on response is central to the precision medicine paradigm and min-maxing healthcare resource.  This is why the recent STARDUST study published in Lancet Gastro may have left a few people disappointed where […]

Before I worked at Motilent, I was a teaching assistant at a special needs school. Last week, when LEGO MRI scanners started popping up on social media, it made me think of the children I used to work with. For these children, who often struggle with communication, medical appointments can be very scary. MRI is […]

Motilent’s clinically-validated AI software has received 510k clearance from the US FDA. New collaboration with AI-powered solutions provider Nuance Communications will allow US healthcare clinics using innovative GIQuant software to accurately measure intestinal motility and treatment response using AI medical image analysis

Motilent’s CEO and Founder, Alex Menys speaks with Dr James Somauroo on The Health-Tech podcast. In the show Alex and James talk about the challenges of getting a product to market in the Med-Tech space as well as the the role of regulations, evidence and relationship building with the clinical community. There’s also a good […]